Recorded fact · drug.label_indication
drug.label_indication for pirtobrutinib|mantle-cell-lymphoma
One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact a7a1a83d resolves to.
The record
| Fact id | a7a1a83de80582da940342df |
|---|---|
| Entity | drug: pirtobrutinib|mantle-cell-lymphoma |
| Field | drug.label_indication |
| Source | api.fda.gov |
| Read on | 2026-11-10T19:02:47.536Z |
| Source version | openfda-label-20260306 |
| Method | extract |
| Verification | verified |
| Licence | CC0 1.0 per open.fda.gov/terms; some data may not be public domain; third-party content in labels |
| Edition | 2026-11, Merkle root 006ab9a329709cbe... |
The verifying quote
Adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.
Shown with dashes as hyphens. SHA-256 of the exact stored quote: c3a0a9f58b7bbf25490298b76a8effb2642c2e1d2b36c11e6748adc862a00231.
The value
{
"ingredient": "Pirtobrutinib",
"conditionId": "mantle-cell-lymphoma",
"conditionName": "Mantle Cell Lymphoma",
"matchedAlias": "mantle cell lymphoma",
"context": "indication",
"brand": "JAYPIRCA",
"identifiedVia": "product_elements",
"extractor": 5,
"labelSetId": "bd551845-0878-49a4-860f-839b83f6b801",
"labelEffectiveTime": "20260306",
"labelsRead": 1,
"labelsNaming": 1,
"registryEditionRoot": "1b44e76f5da1a417",
"meaning": "the FDA label's Indications and Usage text names this condition; not a statement that the drug is approved, effective or covered for it"
}SHA-256 of the exact stored value: 988ea81559cfb4e904ccc9172a211453bc24a0c1fd5293d3be91ba83df0c246e.
This fact as data (JSON) · Check an answer against its receipt · Licence
Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.